HealthEquity: Compounding Flywheel Reveals Attractive Entry Point (NASDAQ:HQY)
· seekingalpha.com
HealthEquity is rated a Buy with a $115 price target, supported by catalysts, margin gains, and share buybacks. Read more on HQY stock here.
HealthEquity's high-quality compounding business model has fallen roughly 15% over the past year, despite delivering constant revenue growth, expanding margins,...